文献速递肿瘤 PET/CT

合格校准本地网络中癌症患者18F-FDG PET/CT摄取的测试-重测可重复性

Test-Retest Reproducibility of 18F-FDG PET/CT Uptake in Cancer Patients Within a Qualified and Calibrated Local Network.
PubMed 文献 · J Nucl Med · 2018-10-25

研究评估了多中心合格校准的18F-FDG PET/CT扫描仪在癌症患者中测试-重测SUV的可重复性。共评估162个病灶,同一机构内相同或同型号扫描仪的平均SUVmax差异为8%(95%CI 6%-10%),不同机构不同型号扫描仪为18%(95%CI 13%-24%)。结论认为扫描仪资格认证和校准可获得高度可重复的肿瘤SUV测量,支持使用同型号合格扫描仪进行系列研究,不同型号扫描仪的差异较大。

要点

  • 同一机构内相同或同型号扫描仪测试-重测病灶SUVmax平均差异8%(95%CI 6%-10%)。
  • 不同机构不同型号扫描仪测试-重测病灶SUVmax平均差异18%(95%CI 13%-24%)。
  • 正常肝SUVmean平均差异在同型号或同机构为5%(95%CI 3%-10%),不同机构不同型号为6%(95%CI 3%-11%)。

核心结论

  • 18F-FDG PET/CT扫描仪资格认证和校准可获得高度可重复的测试-重测肿瘤SUV测量。
  • 数据支持使用同型号的不同合格扫描仪进行系列研究。
  • 不同型号扫描仪的测试-重测差异较大,更依赖分辨率的扫描仪协议和重建算法协调可能能够将这些差异降低到更接近同扫描仪结果的值。

研究设计与样本

  • 采用美国国家标准与技术研究院可溯源参考源对扫描仪和剂量校准器进行多中心资格认证流程,并使用相似的患者和成像协议。
  • 纳入5台来自4个机构的18F-FDG PET/CT扫描仪(2台在National Cancer Institute指定的综合癌症中心,3台在社区网络)进行资格认证用于研究。
  • 患者在15天内扫描两次,条件为:同一扫描仪(n=10);同一机构内不同但同型号扫描仪(n=2);或不同机构不同型号扫描仪(n=11)。
  • 记录病灶SUVmax和正常肝摄取SUVmean,使用线性混合模型评估测试-重测差异并估计一致性相关系数,生成Bland-Altman图和重复性系数。
  • 共评估6例患者(乳腺癌n=17,其他癌症n=6)的162个病灶(骨82,软组织80)。

主要发现

  • 同一机构内使用相同扫描仪或2台同型号扫描仪,病灶SUVmax平均差异为8%(95%CI 6%-10%)。
  • 不同机构不同扫描仪测试-重测病灶SUVmax平均差异为18%(95%CI 13%-24%)。
  • 正常肝SUVmean平均差异在同型号或同机构为5%(95%CI 3%-10%),不同机构不同扫描仪为6%(95%CI 3%-11%)。
  • 协议依从性良好,注射至采集时间中位差异为2分钟(范围0-11分钟)。
  • 测试-重测SUVmax变异性未由现有协议偏差或患者或病灶特征信息解释。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Calibration and reproducibility of quantitative 18F-FDG PET measures are essential for adopting integral 18F-FDG PET/CT biomarkers and response measures in multicenter clinical trials. We implemented a multicenter qualification process using National Institute of Standards and Technology-traceable reference sources for scanners and dose calibrators, and similar patient and imaging protocols. We then assessed SUV in patient test-retest studies. Methods: Five 18F-FDG PET/CT scanners from 4 institutions (2 in a National Cancer Institute-designated Comprehensive Cancer Center, 3 in a community-based network) were qualified for study use. Patients were scanned twice within 15 d, on the same scanner (n = 10); different but same model scanners within an institution (n = 2); or different model scanners at different institutions (n = 11). SUVmax was recorded for lesions, and SUVmean for normal liver uptake. Linear mixed models with random intercept were fitted to evaluate test-retest differences in multiple lesions per patient and to estimate the concordance correlation coefficient. Bland-Altman plots and repeatability coefficients were also produced. Results: In total, 162 lesions (82 bone, 80 soft tissue) were assessed in patients with breast cancer (n = 17) or other cancers (n = 6). Repeat scans within the same institution, using the same scanner or 2 scanners of the same model, had an average difference in SUVmax of 8% (95% confidence interval, 6%-10%). For test-retest on different scanners at different sites, the average difference in lesion SUVmax was 18% (95% confidence interval, 13%-24%). Normal liver uptake (SUVmean) showed an average difference of 5% (95% confidence interval, 3%-10%) for the same scanner model or institution and 6% (95% confidence interval, 3%-11%) for different scanners from different institutions. Protocol adherence was good; the median difference in injection-to-acquisition time was 2 min (range, 0-11 min). Test-retest SUVmax variability was not explained by available information on protocol deviations or patient or lesion characteristics. Conclusion:18F-FDG PET/CT scanner qualification and calibration can yield highly reproducible test-retest tumor SUV measurements. Our data support use of different qualified scanners of the same model for serial studies. Test-retest differences from different scanner models were greater; more resolution-dependent harmonization of scanner protocols and reconstruction algorithms may be capable of reducing these differences to values closer to same-scanner results.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Kurland BF, Peterson LM, Shields AT, et al. Test-Retest Reproducibility of 18F-FDG PET/CT Uptake in Cancer Patients Within a Qualified and Calibrated Local Network. J Nucl Med. 2018. PMID: 30361381. doi:10.2967/jnumed.118.209544

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。